Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.

Completed

• Conditions: Ards; Extracorporeal Membrane Oxygenation; Mechanical Ventilation Pressure High

• Registration Number: NCT05341687
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Mortality of patients with COVID-19 associated acute respiratory distress syndrome (CARDS) treated with veno-venous extra-corporal membrane oxygenation (vv-ECMO) is increasing over time since the beginning of the COVID-19 pandemic. The objectives were to retrospectively describe over the first ten days after vv-ECMO implantation, the ventilatory management of CARDS and to assess the impact of static respiratory system compliance (CRS) on the first day of vv-ECMO on 180-day mortality.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-03
• Primary Completion: 2021-12-31
• Study First Submitted: 2022-04-14
• Study First Submitted QC: 2022-04-20
• Study First Posted: 2022-04-22
• Study Completion: 2023-05-01
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-16
• Last Update Posted: 2024-07-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 122

Inclusion Criteria

• Patients with ARDS secondary to COVID-19 pneumonia requiring ECMO-VV support, hospitalized in the intensive care units of the CHRU of Nancy, Marseille or Bordeaux between 01/03/2020 and 31/12/2021.
• Age > 18 years old

Exclusion Criteria

• Respiratory parameters not available on ten first day of VV ECMO implantation.
• Patient refusal to participate in the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vital status (dead or alive)	Days, 10.	according to compliance during the first ten days of VV ECMO implantation

Secondary Outcome Measures

Name	Time	Method
Evolution of driving pressure	Days, 10	after VV-ECMO implantation
Evolution of PEEP	days, 10	after VV-ECMO implantation
Evolution of tidal volume	Days, 10	after VV-ECMO implantation

Trial Locations

Locations (1)

CHU Nancy; 🇫🇷 Nancy, France